title: Effects of non-ionic monomeric and dimeric iodinated contrast media on renal and systemic haemodynamics in rats.
abstract: Non-ionic dimeric contrast media (CM) are a new class of CM which are iso-osmolar with plasma. The aim of this study was to investigate their effects on systemic and renal haemodynamics. The non-ionic dimeric CM iodixanol and the non-ionic monomeric agent iobitridol (both at a dose of 1,600 mgI/kg) were compared in terms of their effects on systemic blood pressure (BP) and renal blood flow (RBF) in two strains of rats (Wistar and Sprague Dawley). Iodixanol significantly lowered BP in Wistar rats (-33 +/- 9% of baseline, 10 min post-injection, P < 0.001 vs. saline and iobitridol). Iobitridol had virtually no effect on BP. Iobitridol and iodixanol significantly decreased RBF. This effect was more marked following injection of the dimer rather than the monomer (iodixanol: -32 +/- 13% iobitridol: -20 +/- 4 of baseline at 16 min, P < 0.05). For both agents, RBF was still decreased 50 min following injection (iodixanol: -30 +/- 11%, and iobitridol: -20 +/- 5% of baseline). Iodixanol also decreased RBF in Sprague Dawley rats, while BP remained unchanged. This suggests that changes in BP/RBF autoregulation do not account for the renal haemodynamic effects of this agent. When measured 2 h following injection, the iodixanol-induced renal hypoperfusion was still detectable (-29% vs. saline-treated rats), although not significant (P = 0.06). This effect was no longer observed 4 h following injection. Increasing the saline infusion rate (18 mL/h vs. 2 mL/h) during the experiment did not significantly decrease the effects of iodixanol on BP and RBF in Wistar rats. In spite of its iso-osmolality, iodixanol, a non-ionic dimeric CM, depressed RBF and BP significantly more than iobitridol, a monomeric non-ionic agent, in Wistar rats. This effect was long-lasting and was not alleviated by increasing the hydration rate.
authors.affiliation: Laboratoire Guerbet, Biology Department, Roissy-Charles de Gaulle, France. ideej@guerbet-group.com
authors.forename: J M
authors.initials: JM
authors.lastname: Idée
authors.forename: E
authors.initials: E
authors.lastname: Lancelot
authors.forename: C
authors.initials: C
authors.lastname: Berthommier
authors.forename: V
authors.initials: V
authors.lastname: Couturier-Goulas
authors.forename: V
authors.initials: V
authors.lastname: Vazin
authors.forename: C
authors.initials: C
authors.lastname: Corot
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001834:Body Water / Q000502:physiology; D003287:Contrast Media / Q000008:administration & dosage / Q000633:toxicity*; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects*; D007275:Injections, Intravenous; D007472:Iohexol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012079:Renal Circulation / Q000187:drug effects*; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000633:toxicity*; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids; C093233:iobitridol; D007472:Iohexol; C044834:iodixanol